Last Updated 14 December 2015 The large therapeutic market for chronic obstructive pulmonary disease (COPD), a disease that is closely associated with smoking, continues to expand. The prevalence…
Last Updated 14 December 2015 The rheumatoid arthritis (RA) therapy market has matured to the point that TNF-α inhibitors have become firmly established as first-line biological agents, leaving…
The entrenched positioning of biologics (in particular, tumor necrosis factor-alpha [TNF-alpha] inhibitors) to treat moderate-to-severe rheumatoid arthritis (RA) has generated a multi-billion-…
TreatmentTrends: Diabetic Retinopathy/Diabetic Macular Edema (EU) is the inaugural report in an annual syndicated report series that offers a snapshot of the diabetic retinopathy (DR) and diabetic…
Methicillin-resistant Staphylococcus aureus (MRSA) is a clinically important Gram-positive pathogen in both the hospital and outpatient settings. The recent FDA approvals of oritavancin (The…
Through comprehensive primary research methods, the TreatmentTrends: Rheumatoid Arthritis 2015 (US) report explores the treatment dynamics among 100 U.S. rheumatologists and how these have evolved…
The 2014 multiple myeloma market garnered impressive sales despite its relatively low incidence compared with other oncology markets with similar revenues. Significant achievements in clinical…
LaunchTrends: Keytruda Wave 3 (US) is the third in a series of syndicated reports designed to track physician perception, uptake, and competitive environment regarding the malignant melanoma drug…
Bipolar disorder (BPD) is a debilitating psychiatric illness affecting more than 20 million people across the seven major pharmaceutical markets under study (United States, France, Germany, Italy,…
Bipolar disorder (BPD) is a debilitating psychiatric illness affecting more than 20 million people across the seven major pharmaceutical markets under study (United States, France, Germany, Italy,…
The availability of novel disease-modifying therapies (DMTs)—Copaxone 40 mg 3TW, oral DMTs, Plegridy, and Lemtrada—has complicated clinical decision-making and treatment choice in the…
The U.S. Physician and Payer Perspectives on Novel Treatment Options for Prostate Cancer report surveyed 50 medical oncologists, 52 urologists, and 30 MCO pharmacy and medical directors to capture…
Mutations in the gene coding for C1-inhibitor (C1-INH) protein result in hereditary angioedema (HAE), whereby insufficient levels of C1-INH or abnormal forms of the protein ultimately result in…
Mutations in the gene coding for C1-inhibitor (C1-INH) protein result in hereditary angioedema (HAE), whereby insufficient levels of C1-INH or abnormal forms of the protein ultimately result in…
LaunchTrends: Cosentyx (US) is a three-wave syndicated report series that specifically tracks the introduction of Novartis’s Cosentyx (secukinumab), a potent, subcutaneous IL-17 inhibitor…